Protalix BioTherapeutics (PLX) EPS (Diluted) Growth (1y) (2012 - 2026)
Protalix BioTherapeutics (PLX) EPS (Diluted) Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 36.94% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17,091.12% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 61.58% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.16% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 96.09% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 568.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 568.72% |
| Dec 31, 2025 | -134.23% |
| Sep 30, 2025 | -30.13% |
| Jun 30, 2025 | 116.17% |
| Mar 31, 2025 | 24.92% |
| Dec 31, 2024 | 154.60% |
| Sep 30, 2024 | 293.40% |
| Jun 30, 2024 | -115.43% |
| Mar 31, 2024 | -15.50% |
| Dec 31, 2023 | -268.68% |
| Sep 30, 2023 | 69.33% |
| Jun 30, 2023 | 272.86% |
| Mar 31, 2023 | -9.24% |
| Dec 31, 2022 | 49.84% |
| Sep 30, 2022 | 23.56% |
| Jun 30, 2022 | 54.96% |
| Mar 31, 2022 | 66.02% |
| Dec 31, 2021 | -168.18% |
| Sep 30, 2021 | 31.98% |
| Jun 30, 2021 | 11.35% |